港股異動 | 中芯國際升近8%再創新高,將於明日確定科創板發行價
uSMART友信智投7月2日消息,週四港股開市,中芯國際高開高走,股價再創新高,截至10:10分,中芯國際升7.59%,報29.1港元。
6月30日晚間,上交所官網顯示,中芯國際(00981)科創板IPO註冊生效同日中芯發佈招股意向書及相關發行安排,7月1日開啟網下路演,將於7月3日確定發行價。
據彭博獲取的中芯國際聯席保薦機構的投價報告稱,中芯國際科創版IPO的合理估值區間在38.29到44.43元人民幣。
中芯國際的聯席保薦機構為海通證券和中金公司,參考價格區間並非正式發行價格區間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.